Martina Meocci

Dr. Martina Meocci


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
TPTommaso PIANIGIANI
Tommaso PIANIGIANI
LALorenzo Alderighi
Lorenzo Alderighi
MMMartina Meocci
Martina Meocci
MMMaddalena Messina
Maddalena Messina
BPBeatrice Perea
Beatrice Perea
PCPaolo Cameli
Paolo Cameli
Background: Fractional exhaled nitric oxide (FeNO) is a biomarker of airway inflammation associated with airway hyper-responsiveness and type-2 inflammation. Its role in the management of severe asthmatic patients undergoing biologic treatment, as well as FeNO dynamics during biologic treatment, is largely unexplored. Purpose: The aim was to evaluate published data contributing to the following areas: (1) FeNO as a predictive biomarker of response to biologic treatment; (2) the influence of biologic treatment in FeNO values; (3) FeNO as a biomarker for the prediction of exacerbations in patients treated with biologics. Methods: The systematic search was conducted on the Medline database through the Pubmed search engine, including all studies from 2009 to the present. Results: Higher baseline values of FeNO are associated with better clinical control in patients treated with omalizumab, dupilumab, and tezepelumab. FeNO dynamics during biologic treatment highlights a clear reduction in FeNO values in patients treated with anti-IL4/13 and anti-IL13, as well as in patients treated with tezepelumab. During the treatment, FeNO may help to predict clinical worsening and to differentiate eosinophilic from non-eosinophilic exacerbations. Conclusions: Higher baseline FeNO levels appear to be associated with a greater benefit in terms of clinical control and reduction of exacerbation rate, while FeNO dynamics during biologic treatment remains a largely unexplored issue since few studies have investigated it as a primary outcome. FeNO remains detectable during biologic treatment, but its potential utility as a biomarker of clinical control is still unclear and represents an interesting research area to be developed.

Verified
Journal Article
Open access
PDF file
laura bergantinilaura bergantini
laura bergantini
Miriana D'AlessandroMiriana D'Alessandro
Miriana D'Alessandro
SGSara Gangi
Sara Gangi
FBFrancesco Bianchi
Francesco Bianchi
PCPaolo Cameli
Paolo Cameli
Elena BargagliElena Bargagli
Elena Bargagli
Coronavirus disease 2019 (COVID-19) may determine a multisystemic chronic syndrome after resolution of SARS-CoV-2 infection in a significant percentage of patients. Persistent cytokine dysregulation can contribute to long-lasting inflammation and tissue damage, resulting in the diverse, often debilitating symptoms experienced by some patients (so-called long COVID syndrome). The aim of our study was to evaluate the value of a panel of serum biomarkers of severity and prognosis in patients hospitalized for COVID-19 and also as predictive factors for the development of post-COVID lung sequelae after discharge from the hospital. All blood sampling was performed in the first 24 h after admission to the hospital. Serum analyte concentrations of IL-4, IL-2, CXCL10 (IP-10), IL-1β, TNF-α, CCL2 (MCP-1), IL-17A, IL-6, IL-10, IFN-γ, IL-12p70 and TGF-β1 were quantified by bead-based multiplex LEGENDplex™ analysis and commercially available ELISA kits. A total of 108 COVID-19 patients were enrolled in the study. Comparative analysis of these proteins showed higher levels of TGF-β and IL-6 and lower levels of RBP-4 and IL-10 in the severe group. Age, adiponectin, IL-8 and IL-32 resulted as the best predictors for survival. Moreover, IL-1β, IL17A, TNF-α, TGF-β, IL-4 and IL-6 were significantly higher in patients who showed HRCT evidence of fibrotic interstitial alterations at follow-up than patients who did not. The initial inflammatory status of patients on admission to the hospital with COVID-19, as reflected by the present panel of adipose tissue-related biomarkers and cytokines, offered insights into medium-term prognosis.

14 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TPTommaso PIANIGIANI
Tommaso PIANIGIANI
ADAkter Dilroba
Akter Dilroba
MMMichael McConville
Michael McConville
SBSamantha Banford
Samantha Banford
MMMartina Meocci
Martina Meocci
PCPaolo Cameli
Paolo Cameli
Background: Interstitial lung disease (ILD) is an increasingly recognized manifestation of ANCA-associated vasculitis (AAV) and is associated with substantial morbidity and mortality. The marked biological and clinical heterogeneity of AAV-associated ILD (AAV-ILD) poses major challenges for diagnosis, prognostic stratification, and therapeutic decision-making. Circulating biomarkers have emerged as promising tools for improving disease characterization; however, the available evidence remains limited and fragmented. Methods: We performed a scoping review to summarize the current evidence on circulating biomarkers investigated in AAV-ILD. Peer-reviewed studies evaluating biomarkers associated with ILD occurrence, disease activity, radiological progression, pulmonary function decline, mortality, or treatment response were systematically identified and qualitatively analyzed. Results: Six observational studies met the inclusion criteria, comprising four retrospective and two prospective cohorts. The identified biomarkers could be broadly classified into three biological categories: epithelial injury biomarkers (KL-6 and surfactant protein D [SP-D]), immune–fibrotic biomarkers (C-C motif chemokine ligand 2 [CCL2] and C-X-C motif chemokine ligand 6 [CXCL6]), and epithelial remodelling biomarkers (carbohydrate antigen 19-9 [CA19-9], cancer antigen 125 [CA125], and cytokeratin-19 fragment [CYFRA21-1]). KL-6 and SP-D were consistently associated with pulmonary involvement, disease activity, and relapse, whereas CCL2 and CXCL6 reflected inflammatory and profibrotic pathways linked to disease progression. Tumour-associated biomarkers were associated with radiological abnormalities and mortality,suggesting that they may reflect aberrant epithelial remodelling rather than malignancy. Across studies, circulating biomarkers showed potential utility for disease detection, prognostic stratification, longitudinal monitoring, and therapeutic guidance. However, the current evidence is limited by small sample sizes, retrospective study designs, and substantial clinical heterogeneity. Conclusions: Circulating biomarkers represent a promising approach for improving the biological characterization of AAV-ILD and may facilitate more personalized management strategies by distinguishing inflammatory from fibrotic disease phenotypes. Prospective multicentre studies with independent validation cohorts are required before biomarker-guided management can be implemented in routine clinical practice.

29 September 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
TPTommaso PIANIGIANI
Tommaso PIANIGIANI
ADAkter Dilroba
Akter Dilroba
MMMichael McConville
Michael McConville
SBSamantha Banford
Samantha Banford
MMMartina Meocci
Martina Meocci
PCPaolo Cameli
Paolo Cameli
Background: Interstitial lung disease (ILD) is an increasingly recognized manifestation of ANCA-associated vasculitis (AAV) and is associated with substantial morbidity and mortality. The marked biological and clinical heterogeneity of AAV-associated ILD (AAV-ILD) poses major challenges for diagnosis, prognostic stratification, and therapeutic decision-making. Circulating biomarkers have emerged as promising tools for improving disease characterization; however, the available evidence remains limited and fragmented. Methods: We performed a scoping review to summarize the current evidence on circulating biomarkers investigated in AAV-ILD. Peer-reviewed studies evaluating biomarkers associated with ILD occurrence, disease activity, radiological progression, pulmonary function decline, mortality, or treatment response were systematically identified and qualitatively analyzed. Results: Seven observational studies met the inclusion criteria. The identified biomarkers could be broadly classified into three biological categories: epithelial injury biomarkers (KL-6 and SP-D), immune–fibrotic biomarkers (CCL2, CXCL6, CXCL13, and IL-13), and epithelial remodelling biomarkers (CA19-9, CA125, and CYFRA21-1). KL-6 and SP-D were associated across individual studies with pulmonary involvement, disease activity, or relapse, whereas CCL2, CXCL6, CXCL13, and IL-13 were associated with inflammatory and profibrotic processes, radiological abnormalities, or disease progression. Tumour-associated biomarkers were associated with radiological abnormalities and mortality, suggesting that they may reflect aberrant epithelial remodelling rather than malignancy. Across studies, circulating biomarkers showed preliminary associations with disease detection, prognosis, longitudinal disease behaviour, and treatment response; however, their clinical utility has not been prospectively established. Overall, the current evidence is limited by small sample sizes, retrospective study designs, and substantial clinical heterogeneity. Conclusions: Circulating biomarkers represent a promising approach for improving the biological characterization of AAV-ILD and may contribute to the future characterization of inflammatory and fibrotic disease phenotypes. Prospective multicentre studies with independent validation cohorts are required before biomarker-guided management can be implemented in routine clinical practice.